Carasent AB (publ) (APXZF) Q1 2026 Earnings Call Transcript

Carasent reported 16% ARR growth in Q1 2026, with recurring revenues above 95% and net revenue retention of 111%. Management said nearly 80% of growth translated into profitability, though consulting revenue was low and remains outside the company's focus. The update signals solid operational execution and continued scalable growth.

Analysis

The key signal is not simply growth, but the quality of growth: high recurring revenue plus sub-100% conversion of incremental revenue into profit implies the business is entering a favorable operating leverage phase. That tends to rerate software-like healthcare IT platforms because investors begin underwriting duration of cash flows rather than one-off implementation revenue, which compresses perceived cyclicality and lowers discount rates.

The underappreciated second-order effect is competitive: if core demand is coming from private clinics and hospitals, the vendor with the stickiest workflow integration should continue to pull share while smaller point-solution rivals struggle to match both product breadth and margin discipline. Low consulting mix is a positive for valuation multiples, but it can also mask weaker implementation land-and-expand activity; if that mix stays low for multiple quarters, the market may start questioning whether new logo acquisition is slowing even as ARR stays healthy.

The main risk is that this is a quality story that can still de-rate if ARR decelerates from 16% to low teens over the next 2-3 quarters. Because the stock is likely trading more on revenue durability than near-term earnings, the next catalyst is not just another quarter of growth, but evidence that net revenue retention remains above 110% while margin expansion continues; any slip there would likely hit the multiple before the P&L.

Contrarian take: consensus may be underestimating how much of the current optimism is already embedded in the stock after a clean quarter. The better setup may be to buy on a post-print pullback if management can maintain this operating cadence, rather than chase strength immediately; the asymmetry improves if the market gives back 8-12% on any disappointment in consulting or headline ARR growth while the underlying recurring engine remains intact.

Key Decisions for Investors

• Long APXZF on a 3-6 month horizon if the shares are not already pricing >15% ARR growth and continued NRR >110%; risk/reward favors re-entry on any 8-12% post-earnings pullback rather than immediate momentum chasing.
• If APXZF is available only through ADR liquidity, use a staggered build over 2-3 sessions to minimize spread risk; the catalyst is multi-quarter operating leverage, not a one-day move.
• Pair trade: long APXZF / short a lower-quality healthcare software peer with heavier services mix and weaker retention metrics over the next 1-2 quarters; the relative trade benefits if the market keeps rewarding recurring revenue and margin conversion.
• Tighten risk if ARR growth drops below ~14% or NRR slips under 108% in the next two reports; that would likely trigger multiple compression before earnings estimates are meaningfully cut.
• For options-accessible exposure, consider a 3-4 month call spread funded by selling upside into the next earnings cycle; the thesis is measured rerating, not explosive gap risk.